Allied Academies every year hosts interdisciplinary international conferences worldwide on cutting-edge basic and applied research in life sciences, Pharma, medicine, healthcare and nursing delivered by the best talents in industry and academia. Our conferences are oriented to drive the scientific community at large, facilitating access to the newest technical and scientific achievements and to shape future research directions through the publication of applied and theoretical research findings of the highest quality.
Allied Academies invites all the participants from all across the globe to attend "World Vaccine and Immunology Congress”, on July 23-24, 2018 in Osaka, Japan which includes prompt keynote presentations, poster presentations, oral talks, and exhibitions.
Vaccines Congress 2018 aims to unite the Professors, researchers, business mammoths, and technocrats to give a global gathering to the spread of unique research comes about, new thoughts and viable improvement and find progresses in the field of Vaccine, Immunization and Vaccination, administration and instruction in connection to Vaccine, Immunization and Vaccination and additionally an expansiveness of different subjects.
· Meet experts and influences face to face.
· Conferences provide a great opportunity to network where most people can help each other uncover ideas and spark inspiration.
·To learn new things in your field
· Conferences Build Your Knowledge Base
· Encounter new vendors and suppliers
· Attending a conference allows you to grow and challenge yourself
· Attending conferences grow your professional network
· Position your company as a champion
· Network with leaders and influencers from the scientific, academic and R&D communities
Vaccines Congress 2018 extends the heartiest welcome to proficient delegates, scientists, professors, students, young researchers, business executives, scholars, chemists and professionals across the globe to be a part of “World Vaccines and Immunology Congress", during July 23-24, 2018, to be held at Osaka, Japan. Keynote presentations, exhibitions, oral talks and poster presentations outline the key attractions of the conference on the theme "Explore the Intriguing Ideas in the Arena of Vaccines."
Allied Academies organizes Vaccines Congress 2018 along with 500+ Conferences across USA, Europe & Asia every year with support from 1000 more scientific societies and Publishes 400+ Open access journals which contain over 30000 eminent personalities as editorial board members.
We invite you to join us at the Vaccines Congress 2018, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Vaccines Congress 2018 organizing committee look forward to meeting you in Osaka, Japan.
Sessions and Tracks
Session 1: Vaccines and Vaccination
A vaccine is a biological formation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that features a disease-causing microorganism and is often made from weakened or killed forms of the micro-organism, its toxins, or one of its surface proteins. They create immunity against a disease. A Traditional vaccine consists of agents that resemble the disease- causing organism. When these agents enter the human body they stimulate the immune system to recognize these agents as foreign and destroy them. It also makes the immune system remember these foreign agents so that they can recognize and destroy the real live virulent germs. A vaccine can be administered into the body through injections, by mouth or by aerosol.
Following are the issues majorly studied in vaccines.
· Vaccine Safety
· Vaccine Work
· Vaccine Type
· Vaccine Ingredients
Session 2: Types of vaccines
Depending upon the strategies used to reduce the risk of illness caused by a vaccine, while retaining their ability to induce a beneficial immune response they are classified into various types. The human vaccines against viruses were made using weaker or attenuated viruses whereas a small pox vaccine is made of cowpox, a poxvirus similar enough to smallpox virus to create immunity. Several different processes are involved in vaccine production based on which they are classified into different types.
• Live attenuated vaccines
• Inactivated/ Killed vaccines
• Subunit/ Conjugate
Session 3: Vaccination and Immunisation
A vaccination is the injection of a killed or weakened organism to boost the immune system’s ability to fight against that organism. Vaccination is a suspension of attenuated or killed microorganisms that are administered for prevention or treatment of infectious disease. The vaccination helps the immune system to recognize and fight specific germs. Perfect immunity against a disease is not guaranteed through vaccination. Immunization refers to making someone immune against infections or diseases. Immunization is not only caused by vaccines but there are also some diseases that cause immunization after an individual encounters and recovers from that disease.
• Active Immunization
• Passive Immunization
• Chickenpox vaccine
• Diphtheria, Tetanus, Pertussis, and Polio vaccine
• Haemophilus influenzae type b vaccine
• Hepatitis B vaccine
• Influenza vaccine
• Meningococcal vaccine
• Pneumococcal vaccine
Session 4: Clinical and Vaccine Immunology
Clinical Immunology deals with the study of diseases and disorders that occurs as a result of weak immune system which includes aberrant action, failure, and abnormal growth of the cellular elements of the immune system. It also deals with diseases related to other systems, where immune responses play a role. Vaccine Immunology deals with the study of vaccines and their immunological effects. It deals with immunological vaccines, their synthesis, development and therapeutic desirability and compatibility.
• Immunological and Immune-mediated disorders
• Viral immuno-pathogenesis
Session 5: Vaccine Preventable Diseases
An infectious disease for which an effective preventive vaccine exists is termed as a vaccine-preventable disease. If a person dies from a disease for which vaccines are available then the death is considered as a vaccine -preventable death. Vaccines produced to fight against bacterial and viraldiseases are a part of controlling communicable disease world-wide. Vaccination against a specific disease reduces the social and economic burden of the disease on communities apart from reducing the incidence of that disease.
• Pertussis (whooping cough)
• Poliomyelitis (polio)
• Haemophilus influenzae type b infections
• Hepatitis B
• Pneumococcal infections
Session 6: Plant based Vaccines
The vaccines in which the desired genes that encode the antigen protein for particular disease are inserted into the genome of plant tissue by various methods are termed as plant-based vaccine. The most common methods that are used to produce effective plant- based vaccines are Agrobacterium-mediated gene transfer and Transformation via genetically modified plant virus. However advancements in the field of science and technology developed new approaches such as agro infiltration, biolistic, electroporation, polyethylene glycol treatment and sonication to replace the former methods.
• Plant-Based Vaccines Production
• Direct & Indirect Gene Delivery Method
• Immunogen Design and Gene Synthesis
• Methods to Increase the Efficiency of Gene Delivery
• Challenges of Plant-Based Vaccines
Session 7: Oncolytic Virus Immunotherapy
Oncolytic Virus Immunotherapy exemplifies an exciting cancer treatment which stimulates a patient-specific immune response against cancer by making use of a virus’ ability to replicate and kill tumour tissue selectively. Immune stimulating chemicals are produced by genetically modifying the OncolyticViruses which also makes them more specific for cancer cells. Therapeuticcancer vaccines and mAb therapy are some of the cancer immunotherapies with which Oncolytic virus immunotherapy are often combined.
• Engineering Oncolytic viruses
• Oncolytic behaviour of wild-type viruses
• Tumour cell phenotype
• Inherent tumour physiology
Session 8: Preventive and Therapeutic Cancer Vaccines
The vaccines that prevent an infection which causes cancer are
Preventive Cancer Vaccines. Some of the preventive vaccines available include
the HPV and hepatitis B vaccines which prevents cervical, anal, and head and
neck cancers. On the other hand the vaccines that trigger the immune system to
recognize and destroy certain markers, or antigens, present on or in cancer
cells are termed as Therapeutic Cancer Vaccines
• Vector-based vaccines
• Dendritic cell
• Tumour cell vaccines
• DNA Vaccines
• Protein or Peptide Cancer Vaccines
• Allogenic cancer vaccines
• Autologous cancer vaccines
Session 9: Vaccine Adjuvents
Adjuvants are ingredients of a vaccine that creates a stronger immunity in patient’s body by enhancing and directing the adaptive immune response mediated by lymphocytes B and T cells against the antigens. The vaccines work better with the help of adjuvants. Naturally occurring adjuvants are present in vaccines produced from weakened or dead microorganisms. Adjuvants are used to enhance the immunogenicity of recombinant antigens, to reduce antigen amount, to increase vaccines efficacy and as antigen delivery system for antigen uptake by mucosa.
• Mineral salt adjuvants
• Tensoactive adjuvants
• Adjuvant emulsions
• Carbohydrate adjuvants
• Cancer vaccine adjuvants
Session 10: Vaccines Delivery System
Vaccine Delivery System is used to promote uptake of the vaccines with the help of absorption enhancers in vaccine formulations. Oral Vaccines are notable developments in vaccine delivery technologies. Oral vaccines have many advantages such as no risk of blood contamination; they need not be liquids, as solids they are less prone to damage and spoilage. Lipid-based delivery systems can be used to achieve needle-free delivery systems. Recent developments in vaccine delivery technologies paved way for Single dosage vaccines which are given to prevent four to six diseases.
• Polymers in solid particulate vaccine delivery
• Liposomal delivery systems
• Emulsion delivery systems
• Polymeric nanoparticle delivery systems
• Dendrimer-based delivery systems
Session 11: Biotechnology and Modern Vaccine Technology
Biotechnology is used in the development of vaccine in three different ways: Using a special monoclonal antibody in the separation of pure antigens, using cloned genes for the synthesis of antigens, synthesized proteins used as vaccines. Recombinant vaccines are vaccines produced from recombinant DNA Technology. They are also called as subunit vaccines. It is necessary that the modern biopharmaceutical vaccines are rationally designed with chemical and physical attributes that distinguish the microbes and creates immune response
• Recombinant vaccines
• Hydrophobic Nanoparticle Technology
• Modern vaccine formulation technologies
• TLR Agonists
• Surfaced Arrayed Therapeutics
• Cloned genes
• Synthetic peptides
Session 12: Vaccine Development and Production
Vaccine development involves a combination of public and private and it is a long and complicated process which lasts for around 10- 15 years. Not all vaccines that are designed gets licensed only tiny percentage of candidate vaccine are licensed. This makes the vaccine research and development costs higher. Vaccines are first designed in laboratories and assays are made with animals before they are tested with humans. The vaccine production cycle is quite different from a pharmaceutical product development since vaccines are biological products made from microorganisms. The challenging factors which makes the vaccine development little complicated includes the identification of suitable antigens, delivery methods which are acceptable, adjuvants, difficulties in manufacturing.
• Exploratory stage
• Pre-clinical development
• Clinical Development of Pandemic Vaccines
• Regulatory approval
• Manufacturing process
Session 13: Travel and Edible Vaccines
Travel vaccines are recommended to provide protection against diseases endemic to the country of origin or of destination. They are intended to protect travellers and to prevent disease spread within and between countries. There is no single vaccination schedule that fits all travellers. Each schedule must be individualized according to the traveller’s previous immunizations, health status and risk factors, the countries to be visited, the type and duration of travel, and the amount of time available before departure. Edible vaccines hold great promise as a cost-effective, easy-to-administer, easy-to-store, fail-safe and sociocultural readily acceptable vaccine delivery system, especially for the poor developingcountries. It involves introduction of selected desired genes into plants and then inducing these altered plants to manufacture the encoded proteins.
• Development of edible vaccines
• Application of edible vaccines
• Candidates for edible vaccines
• Advantages of edible vaccines
• Pre-travel vaccination and its wider impact
Session 14: Veterinary Vaccines
Considerable progress has been made in the production of veterinary vaccines whether live or inactivated for animal use during the past two decades with the increasing use of continuous cell lines as a substrate and adoption of the fermenter technology for antigen production. These vaccines are produced for administration to domestic animals or wild species by parenteral or oralroutes according to vaccine characteristics. More recently a third generation of live veterinary rabies vaccine has been developed using recombinant technology. Depending upon the expression system these vaccines are used either parentally or orally. Oral rabies vaccines are widely used in foxes in Europe and in racoons in the USA. Trials are under way for the oral immunization of dogs in developing countries.
• Highly immunogenic inactivated cell culture vaccines
• Third generation of live rabies vaccines
• Live or inactivated veterinary vaccines
• Veterinary vaccines for parenteral use
• Modified live-virus veterinary vaccines for oral immunization of wildlife
• Recombinant veterinary vaccines for oral immunization of wildlife
Session 15: Geriatric Immunization
As we get older, our immune system tends to weaken over time, putting us at higher risk for certain diseases. This is why, in addition to seasonal flu(influenza) vaccine and Td or Tdap vaccine (tetanus, diphtheria, and pertussis), the adults 60 years or older should take Pneumococcal vaccines, which protect against pneumococcal diseases, including infections in the lungs and bloodstream (also recommended for adults younger than 65 years who have certain chronic health conditions) and Zoster vaccine, which protects against shingles.
• Flu shots for seniors
• Immunization schedule for elderly people
• Immunization and its side effects in geriatrics
• Vaccine dosing and administration in older adults
• Pneumococcal polysaccharide vaccines
• Contraindications and precautions during vaccination in geriatrics
• Risk factors in geriatric immunization
Session 16: Current research and future challenges
Vaccine development remains challenging because of the highly sophisticated evasion mechanisms of pathogens for which vaccines are not yet available. Recent years have witnessed both successes and failures of novelvaccine design and the strength of iterative approaches is increasingly appreciated. These combine discovery of novel antigens, adjuvants and vectors in the preclinical stage with computational analyses of clinical data to accelerate vaccine design. Reverse and structural vaccinology have revealed novel antigen candidates and molecular immunology has led to the formulation of promising adjuvants. Gene expression profiles and immune parameters in patients, vaccines and healthy controls have formed the basis for bio-signatures that will provide guidelines for future vaccine design.
• Immunological challenges
• Antigen discovery
• Aspects of pathology and host responses
• Expanded testing and modeling of vaccine
• Chloroplast-derived vaccines antigens and therapeutics
• Chloroplast-derived viral antigens
Session 17: Vaccines and Autism
Vaccinations may be one of the triggers for autism. Substantial data demonstrate immune abnormality in many autistic children consistent with impaired resistance to infection, activation of inflammatory response, and autoimmunity. Impaired resistance may predispose to vaccine injury in autism. A mercurial preservative in childhood Vaccines, thimerosal, may cause direct neurotoxic, immune-depressive, and autoimmune injury and contribute to early-onset and regressed autism. Live viruses in measles, mumps, and rubella(MMR) may result in chronic infection of the gut and trigger regressed autism. Thimerosal injection may potentiate MMR injury.
• Live viruses in measles, mumps, and rubella (MMR)
• Vaccines containing thimerosal
• Simultaneous administration of multiple vaccines
• Autoimmunity in autism
• Depressed resistance in autism
Session 18: Immunization and Bioterrorism
Bioweapons threat could include the deliberate release of a biological agent by attackers that causes one or more variety of different diseases. The use of effective vaccines would likely to protect lives and limit disease spread in a biological weapons emergency. Licensed vaccines are currently available for a few threats, such as anthrax and smallpox, and research is underway to develop and produce vaccines for other threats, such as tularaemia, Ebola Virus, and Marburg virus. Many bioweapon disease threats, however, lack a corresponding vaccine, and for those that do, significant challenges exist to their successful use in an emergency situation.
• Anthrax and Smallpox
• Plague and Tularemia
• Ebola, Marburg, Lassa, and Machupo Virus
• Q fever, Ricin toxin, Typhus fever
Session 19: Vaccines against Drugs
Drug Addiction is a serious problem worldwide. One therapy being investigated is vaccines against drugs of abuse. The antibodies elicited against the drug can take up the drug and prevent it from reaching the reward centres in the brain. Few such vaccines have entered clinical trials, but research is going on apace. Many studies are very promising and more clinicaltrials should be coming out in the near future.
• Drug molecules and immune system
• Methamphetamine vaccines
• Nicotine vaccines
• Cocaine vaccines
• Hapten structure, linkage chemistry, immunogenic proteins, and adjuvants
Session 20: Paediatric Vaccination
Immunization against diseases such as Polio, Tetanus, Diphtheria, and Pertussis saves the lives of approximately three million children each year. Immunization also prevents many more millions from suffering debilitating illness and lifelong disability. Globally, approximately 132 million babies need to be fully immunized each year. In order to meet this need, immunization systems must have adequate resources, trained and motivated staff, and ample vaccines and syringe supplies.
• 5-in-1 vaccines
• Pneumococcal or Pneumo Jab (PCV) vaccines
• Serogroup B meningococcal (MenB) vaccines
• Hib/Meningitis C booster vaccines
• MMR vaccines
• 4-in-1 pre-school booster
• HPV vaccines (girls only)
• Severe reactions to foods, insect stings, and medications (anaphylaxis)
• Neonatal respiratory syncytial virus infection vaccine
Market Analysis Report
Vaccines are becoming an engine for pharmaceutical industry. Newer and more expensive vaccines are coming into the market faster than ever before. Vaccines have an increasing demand, new target population and larger emerging markets. The vaccines market has very specific features, which increase the intricacy of determining and understanding pricing and procurement. Researches in vaccines are focused on new disease targets and new development strategies. Vaccines development is a complex, expensive, and time-consuming process, typically costing $500 million or more and spanning several years.
Global Vaccine Market:
When compared to the overall market for pharmaceuticals the revenue growth contingency in vaccines looks far more favourable. In 2015 revenues earned by vaccines manufacturers worldwide reached $27.6 billion, up 11% from $24.7 billion in 2014, as sales in all segments expanded. The world vaccines market is envisioned to rise at a compound annual rate of 7.6% during 2013–2022, reaching $45.1 billion in 2022 as new product inventions continue and usage of current products expands. The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 32.31 Billion in 2016 at a CAGR of 7.5%.
Osaka is a large port city and commercial centre on the Japanese island of Honshu. It's known for its modern architecture, nightlife and hearty street food. The 16th-century shogun ate Osaka Castle, which has undergone several restorations, is its main historical landmark. It's surrounded by a moat and park with plum, peach and cherry-blossom trees. Sumiyoshi-taisha is among Japan’s oldest Shinto shrines.
Osaka was evaluated in Research & Development only. Osaka currently markets vaccines in Japan only and is growing its vaccine pipeline, including R&D projects for dengue and chikungunya. Osaka performs above average in Research & Development, and has clear access provisions for its late-stage vaccine candidate. While it does not currently market vaccines in countries in scope, it is taking steps to support affordability and supply of vaccines in its pipeline. For example, from 2016, Osaka has been developing a low-cost IPV with support from the Bill & Melinda Gates Foundation. The beginning stages of early traditions of visits to lovely destinations. Japan's rich history can be experienced most wherever in the country. With numerous old royal residences so far remaining the nation over, it's definitely not hard to set aside a trip back in chance to a place that is known for medieval rulers. The Travel and Tourism Competitiveness Report 2017 positions Japan fourth out of 141 countries for the most part, which was the best in Asia. Japan got for the most part high scores in all viewpoints, especially human services and cleanliness, wellbeing and security, social resources and business travel.
Global Statistics of Vaccines
Global Influenza Vaccine Market will Increase to US$ 5.74 Billion by the Year 2022 – Research and Markets.
The study based on Evaluate Pharm survey shows that at the end of 2013 the sales volume of global vaccine market was $ 25.6 billion and is expected to rise to $41.3 billion by 2020.
Associations & Societies Associated with Vaccines in and around Osaka:
• Japanese Society for Immunology (JSI)
• The Japanese Society for Vaccinology
• The Japanese Society of Virology
• The Japanese Association Of Medical Sciences
• Japan Society of Immunology and Reproduction
• Japan Pediatric Society